Patents by Inventor Hans Herweijer

Hans Herweijer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8021875
    Abstract: The present invention relates to compositions and methods for increasing long term expression in vitro and in vivo, comprising sequences and gene expression cassettes that increase expression of genes to which they are operably linked.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: September 20, 2011
    Assignee: Roche Madison Inc.
    Inventors: Christine I. Wooddell, Hans Herweijer
  • Patent number: 7803782
    Abstract: An intravenous delivery method is described that enables delivery of polynucleotides to extravascular cells of a mammalian limb. The method involves the injection of polynucleotides into a distal vein of a limb that is transiently occluded. Polynucleotide delivery is facilitated by rapid injection in sufficient volume to enable extravasation of the solution into surrounding tissue.
    Type: Grant
    Filed: May 27, 2004
    Date of Patent: September 28, 2010
    Assignee: Roche Madison Inc.
    Inventors: James E. Hagstrom, Julia Hegge, Hans Herweijer, Jon A. Wolff
  • Patent number: 7781415
    Abstract: A process for delivering a polynucleotide to a cardiac tissue cell in a mammal is described, comprising introducing a composition consisting of a polynucleotide into a blood vessel and increasing permeability of the blood vessel to the polynucleotide. The polynucleotide can be a small interfering RNA or microRNA and inhibit gene expression in the cell.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: August 24, 2010
    Assignee: Roche Madison Inc.
    Inventors: Hans Herweijer, Julia Hegge, Jon A. Wolff, David L. Lewis
  • Publication number: 20100120152
    Abstract: The present invention relates to compositions and methods for increasing long term expression in vitro and in vivo, comprising sequences and gene expression cassettes that increase expression of genes to which they are operably linked.
    Type: Application
    Filed: August 27, 2002
    Publication date: May 13, 2010
    Inventors: Christine I. Wooddell, Hans Herweijer
  • Patent number: 7601367
    Abstract: Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: October 13, 2009
    Assignee: Mirus Bio LLC
    Inventors: Sean D. Monahan, David L. Lewis, Hans Herweijer, Jon A. Wolff, James E. Hagstrom, Aaron G. Loomis, Vladimir Trubetskoy, Lori Higgs
  • Patent number: 7589059
    Abstract: Disclosed is a system for providing in vivo delivery of molecules or complexes to extravascular mammalian cells using an intravascular administration route. The molecules or complexes are inserted in an injection solution into a mammalian vasculature. Insertion of the injection solution at an appropriate rate transiently increases the volume of extravascular fluid in the tissue thereby facilitating delivery of the molecule to the cell.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: September 15, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, Vladimir G. Budker, Hans Herweijer, James E. Hagstrom, Sean D. Monahan, Julia Hegge, Vladimir Subbotin
  • Patent number: 7473419
    Abstract: Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic acid to an extravascular parenchymal cell.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: January 6, 2009
    Assignee: Roche Madison Inc.
    Inventors: Jon A. Wolff, James E. Hagstrom, Hans Herweijer, Vladimir G. Budker, Julia Hegge
  • Publication number: 20080152661
    Abstract: The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.
    Type: Application
    Filed: August 17, 2007
    Publication date: June 26, 2008
    Inventors: David B. Rozema, Darren H. Wakefield, Jason Klein, So Wong, Jon A. Wolff, David L. Lewis, James E. Hagstrom, Andrei Blokhin, Vladimir Trubetskoy, Hans Herweijer
  • Publication number: 20080075734
    Abstract: Proper timing and combinatorial administration of immunocytokines and Flt3-L combined with vaccination with tumor associated antigens provides an anticancer therapeutic benefit. Sequential administration of GM-CSF after Flt3-L provides improved expansion of mature dendritic cell populations. The expansion of mature dendritic cells can be used to enhance an immune response in the subject.
    Type: Application
    Filed: August 29, 2007
    Publication date: March 27, 2008
    Inventors: Zane Neal, Hans Herweijer
  • Patent number: 7262056
    Abstract: We disclose compositions and processes for enhancing transposon mediated integration of a nucleic acid molecule into another target nucleic acid molecule. Integration by an integrator complex is enhanced by cationic reagents.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: August 28, 2007
    Assignee: Mirus Bio Corporation
    Inventors: Christine Wooddell, Hans Herweijer, Jon A. Wolff
  • Publication number: 20070128169
    Abstract: Described is a process for intravascular delivery of a polynucleotide to an extravascular cell of a mammal to inhibit gene expression. A polynucleotide containing sequence that is similar to a sequence in the gene to be expressed is made and inserted into a vessel in the mammal. The polynucleotide is delivered to a cell wherein expression of the gene is inhibited.
    Type: Application
    Filed: January 4, 2007
    Publication date: June 7, 2007
    Inventors: David Lewis, Jon Wolff, Vladimir Budker, Hans Herweijer, James Hagstrom
  • Patent number: 7192605
    Abstract: The present invention relates to compositions and methods for transferring nucleic acids into cells in vitro and in vivo. The compositions comprise a transfection reagent and one or more detergents. In preferred embodiments, the compositions comprise delivery systems providing nucleic acid transfer complexes that transfect cells with high efficiency.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: March 20, 2007
    Assignee: Mirus Bio Corporation
    Inventors: Hans Herweijer, Vladimir G. Budker
  • Publication number: 20070048254
    Abstract: A method is provided for expanding the population of mature dendritic cells in an individual subject. Proper timing of sequential delivery of Flt3-L and GM-CSF provides improved expansion of mature dendritic cell populations over methods currently employed in the art. The expansion of mature dendritic cells can be used to enhance an immune response in the subject. The mature dendritic cells can also be isolated from the subject for use in biological research.
    Type: Application
    Filed: August 24, 2006
    Publication date: March 1, 2007
    Applicant: MIRUS BIO CORPORATION
    Inventors: Zane Neal, Hans Herweijer
  • Publication number: 20070021364
    Abstract: The present invention relates to methods for delivering a genetic immunogen, comprising a nucleic acid capable of expressing an antigen, optionally complexed with a polymer. The nucleic acid is delivered to the host via hydrodynamic intravascular injection resulting in expression of an encoded antigen in extravascular cells and induction of an antigen-specific immune response.
    Type: Application
    Filed: May 19, 2006
    Publication date: January 25, 2007
    Inventors: Hans Herweijer, Jon Wolff, Mary Bates, Aaron Loomis, Vladimir Trubetskoy
  • Patent number: 7101995
    Abstract: Described is a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: September 5, 2006
    Assignee: Mirus Bio Corporation
    Inventors: David L. Lewis, James E. Hagstrom, Hans Herweijer, Aaron G. Loomis, Sean D. Monahan, Jon A. Wolff
  • Publication number: 20060093584
    Abstract: Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic acid to an extravascular parenchymal cell.
    Type: Application
    Filed: November 7, 2005
    Publication date: May 4, 2006
    Inventors: Jon Wolff, James Hagstrom, Hans Herweijer, Vladimir Budker, Julia Hegge
  • Publication number: 20060063731
    Abstract: A process is provided to deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity to of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs.
    Type: Application
    Filed: September 26, 2005
    Publication date: March 23, 2006
    Inventors: David Lewis, Jon Wolff, Hans Herweijer, James Hagstrom, Aaron Loomis
  • Patent number: 7015040
    Abstract: Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic acid to an extravascular parenchymal cell.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: March 21, 2006
    Assignee: Mirus Bio Corporation
    Inventors: Jon A. Wolff, Vladimir G. Budker, James E. Hagstrom, Julia Hegge, Hans Herweijer
  • Publication number: 20050260270
    Abstract: A process is provided to deliver small interfering RNA to cells in vivo for the purpose of inhibiting gene expression in that cell. The small interfering RNA is less than 50 base-pairs in length. This process is practiced on post-embryonic animals. Inhibition is sequence-specific and relies on sequence identity of the small interfering RNA and the target nucleic acid molecule.
    Type: Application
    Filed: April 25, 2005
    Publication date: November 24, 2005
    Inventors: David Lewis, Hans Herweijer, Jon Wolff, James Hagstrom, Aaron Loomis
  • Publication number: 20050222075
    Abstract: A process for delivering a nucleic acid to a cardiac tissue cell in a mammal is described, comprising introducing a composition consisting of a nucleic acid to a blood vessel, which subsequently delivers the nucleic acid to the cardiac tissue cell. The nucleic acid can be DNA or RNA or plasmid DNA or viral. This process is for purposes of gene therapy, and research.
    Type: Application
    Filed: May 25, 2005
    Publication date: October 6, 2005
    Inventors: Hans Herweijer, Jon Wolff, Matthew Wolff, Larry Whitesell